trending Market Intelligence /marketintelligence/en/news-insights/trending/B4vaxNkt-AOYyTNgp-1TtA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Emerald Health upsizes bought-deal offering to C$12M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Emerald Health upsizes bought-deal offering to C$12M

Emerald Health Therapeutics Inc. upsized a previously announced bought-deal offering to C$12 million from C$10 million.

The company will now sell 8,900,000 units on a bought-deal basis at C$1.35 per unit for total gross proceeds of about C$12 million. It previously planned to sell 7,408,000 units at C$1.35 per unit for total gross proceeds of about C$10 million.

The company agreed to grant the underwriter an overallotment option to buy up to an additional 1,335,000 units, exercisable in whole or in part, at any time on or before the date that is 30 days after the offering closes. If this option is exercised in full, an additional C$1.8 million will be raised and the aggregate proceeds of the offering will be about C$13.8 million.

Emerald intends to use the net proceeds to accelerate facility expansion and for working capital and general corporate purposes.

The offering is expected to close Feb. 10, subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.

Dundee Capital Partners is acting as the underwriter in the offering.